"Angela Valenti" Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Université di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p<0.001, mean±SD) and antigen (2.5±0.8 vs. 3.5±1 ng/ml p<0.001) were significantly lower in NIDDM patients compared to a control group matched for age and sex (n=50). The diabetic patients showed significantly higher levels of fibrinogen (279.7±51 vs. 240+65 mg/dl p<0.001), t-PA (18.6±5 vs. 13.6±5 ng/ml p<0.001) and PAI-1 (193.4±57 vs. 41.6±55 ng/ml p<0.001) compared to controls. NIDDM patients showed a decreased fibrinolytic potential due to increased PAI-1 and decreased UK activity and antigen levels,signs of vascular damage as suggested by increased t-PA levels, and a hypercoagulable characterized by elevated levels of fibrinogen. These findings suggest a potentially important association between NIDDM and a prothrombotic condition.
Alterations in urokinase levels and impairment in fibrinolytic system in non insulin dependent diabetes mellitus (niddm)
Iacoviello L.;
1996-01-01
Abstract
"Angela Valenti" Laboratory of Thrombosis Pharmacology. Istituto Mario Negri, Consorzio Mario Negri Sud, 66030 S. Maria Imbaro, 1 Institute of General Pathology and Oncology, II University ot Naples, Italy, 2 Gaubius Laboratory, TNO-PG, Leiden, The Netherlands and 3 Facolta di Medicina, Université di Chieti, Italy. NIDDM has been associated with an increased incidence of atherothrombotic complications. Abnormalities in the haemostatic system contribute at least in part to the development of atherothrombosis. In particular an increase in fibrinogen levels and a decrease in fibrinolytic potential, mainly due to tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI-1) alterations have been described. However, no informations are presently available on urokinase (UK) levels in NIDDM patients. To analyze the fibrinolytic system in NIDDM, UK activity (BIA = scuPA + tcuPA), UK antigen (ELISA = scuPA + tcuPA + uPA.Inh complex), fibrinogen, t-PA and PAI-1 were studied in 58 patients (22 women and 36 men; age 63±10) with NIDDM. In NIDDM patients there was no increase in UK both activity and antigen after venous stasis. However, the levels of UK activity (1.8±0.6 vs. 2.2±0.6 ng/ml p<0.001, mean±SD) and antigen (2.5±0.8 vs. 3.5±1 ng/ml p<0.001) were significantly lower in NIDDM patients compared to a control group matched for age and sex (n=50). The diabetic patients showed significantly higher levels of fibrinogen (279.7±51 vs. 240+65 mg/dl p<0.001), t-PA (18.6±5 vs. 13.6±5 ng/ml p<0.001) and PAI-1 (193.4±57 vs. 41.6±55 ng/ml p<0.001) compared to controls. NIDDM patients showed a decreased fibrinolytic potential due to increased PAI-1 and decreased UK activity and antigen levels,signs of vascular damage as suggested by increased t-PA levels, and a hypercoagulable characterized by elevated levels of fibrinogen. These findings suggest a potentially important association between NIDDM and a prothrombotic condition.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
